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ABSTRACT 
Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises the 
frequent overexpressing of somatostatin receptors on the tumour cells. This treatment modality has demonstrated 
valuable patient benefits and is well tolerated. However, renal and bone marrow toxicity can become dose 
limiting and persisting. The aim of this thesis was to investigate normal tissue response during 177Lu-
DOTATATE treatment, with focus on kidneys, bone marrow and also the spleen, the organ that receives the 
highest absorbed dose. To enable analysis of bone marrow response to absorbed dose, a novel image-based 
method for bone marrow dosimetry was developed.  
The first paper included, was a pre-clinical study of morphological and biochemical renal changes in nude mice 
injected with 177Lu-, or 90Y-DOTATATE. The remaining three studies evaluated 51 patients with neuroendocrine 
tumours, treated with 177Lu-DOTATATE at Sahlgrenska University Hospital. Patient renal and bone marrow 
function was evaluated and dosimetry was performed for kidneys, bone marrow and spleen utilising planar and 
SPECT images acquired after infusion, and the developed automated segmentation method for bone marrow 
dosimetry.  
Selective morphological changes were quantified in renal cortex of nude mice, and corresponding biochemical 
changes observed, after 177Lu-DOTATATE injection. These appeared in a dose-dependent manner. No 
morphological changes were observed for the animals receiving 90Y-DOTATATE. In the clinical studies, it was 
found that patients with inferior renal function were exposed to higher mean absorbed renal doses, and 
experienced enhanced haematological toxicity. It was also shown that a longer residence time for 177Lu and a 
higher tumour burden increased the haematological toxicity. A novel image-based method for bone marrow 
dosimetry was developed, and correlations were found between mean and total absorbed bone marrow doses, 
and haematological toxicity. The role of the spleen for haematological toxicity was also analysed, and it was 
observed that radiation exposure of the spleen had an impact on the haematological response. The results in this 
thesis emphasise that several parameters affects normal tissue response in 177Lu-DOTATATE treatment. 
Hopefully, a better understanding of what decides the individual response, may contribute to individualised 
treatment decisions in the future.   
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